Drug Profile
Research programme: antibacterials - BioWest
Alternative Names: MBI 2046; MBI 2401; MBI-1396; MX 2401Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ardea Biosciences; BioSource Pharm
- Developer Carrus Capital Corporation
- Class Antibacterials; Lipoproteins; Peptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-positive-infections in Canada (IV)
- 19 Aug 2011 BioWest Therapeutics is now called Carrus Capital Corporation
- 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Gram-positive infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)